Regeneron Pharmaceuticals, Inc. (REGN)
收市後：
| 前收市價 | 906.54 |
| 開市 | 912.68 |
| 買盤 | 889.93 x 100 |
| 賣出價 | 891.41 x 100 |
| 今日波幅 | 877.13 - 915.00 |
| 52 週波幅 | 684.81 - 998.33 |
| 成交量 | |
| 平均成交量 | 466,462 |
| 市值 | 99.503B |
| Beta 值 (5 年，每月) | 0.14 |
| 市盈率 (最近 12 個月) | 26.04 |
| 每股盈利 (最近 12 個月) | 34.20 |
| 業績公佈日 | 2024年5月02日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 1,049.15 |
ZacksEXEL vs. REGN: Which Stock Is the Better Value Option?
EXEL vs. REGN: Which Stock Is the Better Value Option?
ZacksRegeneron (REGN) Reports Next Week: What You Should Expect
Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Reuters
UPDATE 1-AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study
AbbVie said on Thursday its drug, Rinvoq, for treating a type of inflammatory skin condition was found to be more effective than Regeneron Pharmaceuticals and Sanofi's Dupixent in a late-stage head-to-head study. Rinvoq helped 19.9% of patients simultaneously achieve near-complete skin clearance with a no-to-little itch after 16 weeks of treatment, compared with 8.9% of patients treated with Dupixent, the study showed. The study is the first head-to-head trial in adults and adolescents with moderate-to-severe atopic dermatitis and had shown an inadequate response to systemic therapy, AbbVie said.
